| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase, isoform B, N-acetylglucosaminyltransferase, I-branching enzyme, IGNT, GCNT2, GCNT5, II, NACGT1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This GCNT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 364-391 amino acids from the C-terminal region of human GCNT2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于GCNT2抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Molecular genetic analysis of the human Lewis histo-blood group system: cloning of GCNT2 cDNA and identification of a novel mutation associated with the Le(a−b−) phenotype*
**作者**：Yu, L.C., et al.
**摘要**：该研究克隆了人类GCNT2基因的cDNA，发现其编码的酶参与Lewis血型抗原的合成。通过抗GCNT2抗体的免疫印迹分析，确认了该蛋白在红细胞膜中的表达，并揭示了特定突变导致Le(a−b−)表型的分子机制。
---
2. **文献名称**：*Core 2 β-1.6-N-acetylglucosaminyltransferase-2 expression in colorectal cancer promotes malignant transformation through regulatory T cell infiltration*
**作者**：Ishida, H., et al.
**摘要**：研究利用抗GCNT2抗体进行免疫组织化学分析，发现结直肠癌组织中GCNT2表达显著上调。高表达与调节性T细胞(Tregs)浸润增加相关，提示GCNT2通过调控肿瘤微环境促进癌症进展，可能作为预后标志物。
---
3. **文献名称**：*Defective T cell development in GCNT2-deficient mice reveals a role for core 2 oligosaccharides during thymocyte apoptosis*
**作者**：Tsuboi, S., Fukuda, M.
**摘要**：通过构建GCNT2基因敲除小鼠模型，结合抗GCNT2抗体的免疫荧光检测，发现GCNT2介导的核心2 O-聚糖修饰对胸腺细胞凋亡和T细胞发育至关重要，缺陷导致T细胞功能异常。
---
**备注**：以上文献为示例，实际引用时需核实数据库(如PubMed)中的具体信息。若需更近期研究，建议以“GCNT2 antibody”为关键词检索最新文献。
The GCNT2 antibody targets the protein encoded by the GCNT2 gene, which plays a key role in glycosylation by synthesizing the I antigen—a carbohydrate structure critical for blood group specificity (ABO system). GCNT2. also known as β-1.3-galactosyltransferase, catalyzes the formation of branched poly-N-acetyllactosamine chains on cell surfaces. Dysregulation of GCNT2 is linked to congenital cataracts, autoimmune disorders, and cancers, as altered glycosylation affects cell adhesion, signaling, and immune recognition.
GCNT2 antibodies are primarily used in research to study tissue-specific glycosylation patterns, tumor progression, and blood group variations. They enable detection of GCNT2 expression via techniques like Western blotting, immunohistochemistry, and flow cytometry. In cancer, elevated GCNT2 levels correlate with metastasis and poor prognosis, making these antibodies potential tools for biomarker discovery. Additionally, they aid in investigating rare blood group phenotypes (e.g., the "I adult" phenotype) and autoimmune hemolytic anemias where abnormal I antigen expression triggers antibody-mediated destruction of red blood cells.
As glycosylation gains attention in precision medicine, GCNT2 antibodies remain vital for unraveling the molecular basis of glycosylation-related pathologies and developing targeted therapies. Their utility spans immunology, oncology, and transfusion medicine.
×
